Combining with all of our data, our results strongly suggest that WT1 overexpression is an independent and negative prognostic biomarker that could potentially be used to evaluate response to induction chemotherapy and prognosis of AML patients with normal cytogenetics. Here, WT1 is linked to acute myeloid leukemia.